1、April 2024Unleash AIs potentialMeasuring the return frompharmaceutical innovation 14th editionForeword 1Executive summary 2Measuring the return from 4 pharmaceutical innovationRealising efficiency opportunities 8Optimising the value of pipelines 14Strategies to improve productivity 18Key questions f

2、or an optimum R&D strategy 24Endnotes 25Contacts 27ContentsForewordWelcome to Unleash AIs potential,Deloittes fourteenth annual report in our Measuring the return from pharmaceutical innovation series.Our report explores the performance of the biopharmaceutical(biopharma)industry and its ability to

3、generate returns from investment in innovative products in the development pipeline.The current biopharma R&D operating model faces several serious challenges,including ongoing regulatory changes,loss of exclusivity of an unprecedented number of high-value assets,and the rapid pace of scientific and

4、 technological advancements.However,advances in digitalisation and artificial intelligence(AI)present new opportunities to improve R&D productivity,paving the way for a new era of innovation and accelerating patient access to new therapies.As always,our report explores the industrys performance,the

5、changing characteristics of the late-stage portfolios and the opportunities for biopharma companies to improve capital returns.Between 2010 and 2023,our report series has provided insights into the productivity of biopharma R&D.In 2010,we analysed the expected return on investment from the late-stag

6、e pipelines of a cohort of 12 large-cap biopharma companies.Over subsequent years,the composition of our cohort has evolved to now include the top 20 companies by R&D spend in 2020.Our analysis in 2023 shows that following a long-term trend of declining returns that there are some welcome signs of i